San Francisco, California, July 28, 2017: Small molecule therapy largely focus on symptoms of lung infections which has been a big hit into the market, states TMR Research in a research report. The therapy is the emergence of various treatment options which differs in the zone of the target and the action mechanism. The report has been titled, “Lung Infections Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025” where an extensive research on targeted therapies and novel therapies in terms of lung infections were carried out.
Lung infections are categorized into two parts namely bronchitis and pneumonia. The infection influences to build up pus and fluid in the airways of the lung which causes difficulty in breathing. This kind of agony mostly affects the children and the elderly at high risk. Study on etiology has accounted bacteria, mycoplasma and virus as a causative agent of lung infection. The major symptoms of lung infection includes fever, stomach pain, and loss of appetite, vomiting, chest pain and blue colored lips. Due to severe lung infections such primary medical conditions such as pneumonia, tuberculosis, lung cancer and cystic fibrosis have also been noticed. In the section of diagnosis, the report has mentioned such techniques includes Chest X-Ray, blood test, bronchoscopy and pulmonary function tests. Surgical treatment and antibiotics are majorly used to treat various chronic lung infections across all regions.
Fast-growing population and growing prevalence of COPD, pneumonia and asthma augments the global lung infections market. The global geriatric population would increase from 524mn in 2010 to around 2bn by 2050 which would accelerate the growth of the aforementioned market. As per the report, rising awareness among people and using advanced technology in diagnostic tests are predicted as the major driving factors in the global lung infections market. Although, the market is currently restrained by technological complexity and costly diagnostic procedures, stated in the report. Decreasing the time in the process of approving particular drugs and therapies is likely to boost the market over the forecast period. In this way, the market can encourage plenty numbers of market players to come with many innovative treatment options which would broaden the market size. Well-established healthcare with favorable mediclaim policies is also accounted as a key driver to increase demand for lung infections treatment.
Region-wise, the global lung infections market is expected to be led by North America due to a growing demand in diagnostic tests, treatments and for promoting awareness. Europe is also considered as a dominating region in lung infections treatment market. The report says, the region of Asia Pacific is considered as an untapped market for lung infections due to such poor healthcare facilities. Well-constructed healthcare and steady healthcare expenditure are predicted for the further growth in lung infections treatment market in that region over the forecast period. The key players operating in the market are Insmed Incorporated, Bayer AG, Creative Antibiotic Sweden AB, and Destiny Pharma Ltd. among many others.